IDXG — INTERPACE BIOSCIENCES, INC.

OTC · Health Care · Health Care Equipment & Supplies · CIK 1054102 ·
Last close
$1.80
Market Cap
$49.86M
52W High
$2.40
52W Low
$1.56
ADV30
6,987
Next earnings
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 9,032,000 5,904,000 1,123,000 721,000 33,409,000 2,647,000 10,327,000
Dec 2025 9,224,000 6,044,000 1,577,000 22,657,000 33,838,000 2,505,000 11,476,000
Sep 2025 8,756,000 5,439,000 1,145,000 911,000 12,036,000 1,423,000 12,334,000
Jun 2025 9,232,000 5,276,000 -468,000 -640,000 12,335,000 502,000 13,548,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$5,830,000
Investing CF
$-356,000
Financing CF
$-4,431,000
CapEx
$-806,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.77
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-210,805,000
Inventory
$1,114,000
Receivables
$5,649,000
ST Investments
EBIT TTM
$3,943,000
Pretax Income TTM
$3,774,000
Interest Exp TTM
$169,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$36,245,000
EBITDA
$4,514,250
Free Cash Flow
$4,635,500
Enterprise Value
$38,823,520
Total Cash
$2,647,000
Total Debt
$0
Shares Out
27,700,904
Trailing EPS
$0.87
Book Value
$1.01
ROE
213.9%
ROA
10.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 38,728,000 4,084,000 24,575,000 33,838,000 11,476,000 5,831,000
Dec 2024 46,926,000 8,108,000 6,702,000 14,792,000 17,009,000 4,646,000
Dec 2023 40,036,000 3,963,000 1,954,000 13,116,000 68,655,000 3,789,000
Dec 2022 31,838,000 -3,840,000 -21,958,000 15,979,000 79,051,000 -7,692,000

TTM Snapshot

Revenues TTM
$130,374,000
NetIncome TTM
$-7,698,000
OpCashFlow TTM
$0
Assets (Latest)
$115,906,000
Forward EPS
$-0.15

Peers — same industry

TickerNameMarket CapLastDaily %
BEAT HeartBeam, Inc. $49.57M $0.89
BDMD Baird Medical Investment Holdings Ltd $48.59M $1.58
AURX Nuo Therapeutics, Inc. $47.92M $0.99
SRTS Sensus Healthcare, Inc. $52.68M $3.20
COCH Envoy Medical, Inc. $53.82M $0.70

News headlines (Yahoo Finance, 1h cache)

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
2026-05-12 20:06 · Yahoo
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
2026-03-30 20:01 · Yahoo
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
2026-01-20 14:00 · Yahoo
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
2025-12-03 17:12 · Yahoo
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
2025-11-12 21:01 · Yahoo
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
2025-09-15 13:15 · Yahoo
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results
2025-08-07 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.